53 results about "Pancreatic A Cells" patented technology

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

Provided is a method of differentiating human pluripotent stem cells (hPSCs) into mature pancreatic β cells, comprising contacting hPSC-derived, differentiated immature pancreatic β cells with a histone deacetylase (HDAC) inhibitor.

The present disclosure is based, in part, on the study of novel tolerogenic peptides derived from proteins expressed by pancreatic cells, which peptides have been developed for use for antigen-specific immunotherapy of type 1 diabetes mellitus. Disclosed are tolerogenic peptides capable of binding class II MHC molecules independent of antigen processing for use in the treatment of Type 1 diabetes wherein the peptides are derived from proteins expressed by pancreatic cells.

Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secretion a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody and / or an immunosuppressive agent (e.g., anti-CD3 antibody), where said administering is carried out under conditions effective to reverse loss of β-cell mass and function in the subject to treat the subject for the condition associate with insufficient insulin secretion. Also disclosed is a composition and a method of increasing β-cell mass and function in a population of pancreatic beta cells.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD317 + MSC cells and application of the CD317 + MSC cells to treatment of type 2 diabetes mellitus. The invention researches the characteristics of CD317 + cells in a heterogeneous UC-MSC population, and finds that the FACS is more beneficial to screening of CD317 + MSCs, and the number of the CD317 + MSCs is gradually increased in in-vitro culture. The expression quantity of stem cell characteristic-related genes in the CD317 + MSC subgroup is obviously increased, which indicates that the stem cell is possibly in an undifferentiated state or affects the differentiation potential, but the effect is transiently and gradually weakened along with culture, which explains that the pluripotent differentiation potential and the like are not obviously changed and are not associated with other potential stem cell surface antigens. The research also finds that the cell is a more favorable subgroup, has unique pluripotency and repair / substitution characteristics, can realize stem cell rejuvenation phenotype, can improve pancreas beta cell functions, reduces diabetic complications, enables partial patients to be independent of insulin, and improves the treatment effect on type 2 diabetes mellitus.

The present disclosure is based in part on research related to novel tolerogenic peptides derived from proteins expressed by pancreatic cells, developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed are tolerogenic peptides that can bind to MHC class II molecules without relying on antigen processing, and are derived from proteins expressed by pancreatic cells, for use in the treatment of type 1 diabetes.

Methods and compositions for generating human pancreatic beta cells and progenitor cells thereof from human pluripotent stem cells using chemically defined media are disclosed. The method can preliminarily generate FOXA2 + HNFlb + dorsal anterior intestinal endoderm cells (DFECs), and according to the provided method, the cells can be further differentiated into human PTF1A + PDX1 + pancreatic progenitor cells (PPCs) and human INS + PDX + pancreatic beta cells (PBCs). The invention also provides a culture medium, an isolated cell population and a kit.

A method for inducing differentiation into pancreatic α cells, said method comprising: (a) a step for culturing endodermal cells, which are obtained by induced differentiation from pluripotent stem cells, in the presence of a bone morphogenetic protein (BMP) signal inhibitor and retinoic acid or a retinoic acid analog to thereby induce the differentiation thereof into primitive gut tube (PGT) cells; (b) a step for culturing the PGT cells and thus inducing the differentiation thereof into pancreatic endocrine precursor (EP) cells; and (c) a step for culturing the EP cells and thus inducing the differentiation thereof into pancreatic α cells, wherein the aforesaid steps (b) and (c) are carried out in the absence of ascorbic acid.

The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.

The present disclosure provides a use of a substance targeting BRD4 in the preparation of a product related to diabetes. In the present disclosure, it is found that the expression of BRD4 in human diabetic beta cells is significantly reduced, and BRD4 plays an important role in maintaining beta cell maturation and differentiation, and long-term and acute BRD4 deficiency can lead to reduced insulin secretion and down-regulation of differentiation markers, highlighting the key role of BRD4 in pancreatic beta cells, providing a target BRD4 that has a significant impact on diabetes, so that substances targeting BRD4 can help to assess the susceptibility of diabetes, screening, prevention, intervention and treatment of diabetes.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

3D cell cultures and devices for 3D cell culture, and methods of use thereof are provided. In some embodiments, the 3D cell culture comprise pancreatic β cells and can be generated in multi-well plates, allowing for high throughput assays on the cell culture.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal / cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

The present disclosure generally relates to methods, assays, devices and kits for measuring Pancreatic Alpha Cell Protein, detecting early Type 1 diabetes mellitus (T1D), and treating T1D.

An amplifying method of pancreatic cells is provided. The amplifying method includes performing digestion, resuspension, discontinuous density gradient centrifugation treatment and amplifying treatment sequentially. The mammalian pancreatic duct is used as the source of pancreatic precursor-like cells in the amplifying method, and islet cells and acinar cells in the cell clusters obtained by the discontinuous density gradient centrifugation treatment are removed. It is beneficial to improve the yield of the pancreatic precursor-like cells availably, and avoid the ethical restrictions and possible carcinogenic risks caused by using the embryonic stem cells. The amplifying medium used comprises a reprogramming substance composed of several small molecule compounds. It can avoid the risks of non-specific and off-target deletion that are easily caused by the use of the gene-editing methods to change the gene sequence. Also provided is a differentiation method and an application of the pancreatic precursor-like cells obtained by the amplifying method.

The present disclosure relates to a method for the generation of cells of the pancreatic lineage, for example pancreatic islet-like cell aggregates comprising pancreatic β-cells, which method comprises the steps of providing a single cell suspension of a population of endocrine progenitor (EP) cells, allowing said EP cells in single cell suspension to form 3D structures and culturing said cells under conditions permissive of differentiation into pancreatic monohormonal β-cells. The present disclosure also relates to pancreatic islet-like cell aggregates obtainable by said method as well as to medical uses thereof.

To provide a method for producing in vitro functional beta-cells (functional pancreatic beta-cells) and populations of cells resulting from the differentiation of pluripotent stem cells.SOLUTION: A method of differentiating pancreatic endoderm cells into functional beta cells expressing PDX1, NKX6.1, MAFA, UCN3, and SLC2A1, comprises culturing immature pancreatic beta cells in a medium supplemented with (a) an effective amount of T3 and (b) an effective amount of 3-deazaneplanocin A (DEZA), thereby producing functional beta cells expressing insulin.SELECTED DRAWING: None

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.

Disclosed herein are methods of treating a condition associated with insufficiency of insulin secretion in a subject by administering a bispecific tyrosine phosphorylation modulating kinase 1A (DYRK1A) inhibitor, glucagon-like peptide-1 receptor (GLP1R) to a subject in need of treatment of a condition associated with insufficiency of insulin secretion level The present invention relates to a method for treating a condition associated with insufficiency of insulin secretion in a subject, comprising administering to the subject a condition associated with insufficiency of insulin secretion, an agonist and an immunomodulatory monoclonal antibody and / or an immunosuppressant (e.g., an anti-CD3 antibody), where the administration is performed under conditions effective to reverse loss of beta cell quality and function in the subject to treat the condition associated with insufficiency of insulin secretion in the subject. Compositions and methods of increasing beta cell quality and function in a population of pancreatic beta cells are also disclosed.

The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.

A system and a method for predicting insulin resistance and / or pancreatic β-cell function are provided, where a machine learning model is utilized to predict insulin resistance and / or pancreatic a decline of β-cell function of a subject in need thereof based on a feature set extracted from a database. Therefore, clinicians or the subject can be warned to take necessary actions on, and adjust related medical treatment or lifestyle before the subject is diagnosed with diabetes mellitus. In addition, a computer readable medium thereof is also provided.